Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Anaplastic Thyroid Cancer
- BRAF Gene Mutation
- BRAF Mutation-Related Tumors
- Thyroid Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04238624
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Eric Sherman, MD Memorial Sloan Kettering Cancer Center
Get Well Soon